About
Barricade Therapeutics is advancing a first-in-class oral therapy, BT-1501, to treat colorectal cancer. The company is addressing the unmet need for improved therapeutic strategies, particularly as colorectal cancer incidence rises among younger adults and resistance to existing treatments is common.
Technology stack
detected 2026-06-11Est. monthly stack spend~$250/mo
Email
Microsoft 365
Stack
Squarespace
SquarespaceAnalytics
Google Analytics 4
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Barricade Therapeutics do?
Barricade Therapeutics is advancing a first-in-class oral therapy, BT-1501, to treat colorectal cancer. The company is addressing the unmet need for improved therapeutic strategies, particularly as colorectal cancer incidence rises among younger adults and resistance to existing treatments is common.
How much funding has Barricade Therapeutics raised?
Barricade Therapeutics has raised a total of $100M in funding. The most recent round on record is Series B.
Where is Barricade Therapeutics headquartered?
Barricade Therapeutics is headquartered in San Diego, United States.
When was Barricade Therapeutics founded?
Barricade Therapeutics was founded in 2017.
What industry does Barricade Therapeutics operate in?
Barricade Therapeutics operates in Biotech, HealthTech, Drug Discovery, Oncology.
How many employees does Barricade Therapeutics have?
Barricade Therapeutics has approximately 25 people on record.